Beijing Disability Risk and Ageing Monitoring Study (BEAM)

This is a community-based prospective cohort study in Beijing, China. The study has been initialized in 2023 and enrolled older residents. This study aims to develop disability risk assessment standards and an early warning model for older adults.

Study Overview

• Status: Recruiting
• Conditions: Death; Disability; Age Problem
• Intervention / Treatment: Other: No intervention

Detailed Description

This is a community-based prospective cohort study. Individuals who aged 60 years or older, lived in the communities for more than 1 year, and signed the informed consent form were enrolled in the present study. The study has been initialized in 2023 and aimed to develop an early warning model and a series of disability risk assessment methods for older adults. This work consists of three steps as following. First, we will build a community-based cohort and thus set up a database. Second, an intelligence model for disability risk assessment will be developed using the database. Third, a series of procedures will be established according to the risk assessment model.

• Study Type: Observational
• Enrollment (Estimated): 2000

Contacts and Locations

• Study Contact: Name: Yi Tang, MD., PhD; Phone Number: 00861083199456; Email: tangyi@xwhosp.org

Study Locations

• China
  • Beijing, China, 100053
    • Recruiting
    • Xuanwu Hospital, Capital Medical University
    • Contact: Yi Tang, M.D., Ph.D.; Phone Number: 00861083199456; Email: tangyi@xwhosp.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Community residents aged 60 years or older in China

Description

Inclusion Criteria:

• Aged 60 years or older
• Lived in the community for more than 1 year
• Signed the informed consent form

Exclusion Criteria:

• Cannot complete the survey

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Total; All subjects	Other: No intervention; No intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The prevalence and incidence of functional disability using a population-based survey	Functional disability was measured by Activities of Daily Living, cognitive function (Mini-Mental State Examination) and movement disorder（Short Physical Performance Battery) collected by questionnaires.The minimum value of the Activities of Daily Living is 0, and the maximum value is 100, the higher the score, the better the outcome.The minimum value of the Mini-Mental State Examination is 0, and the maximum value is 30, the higher the score, the better the outcome.The minimum value of the Short Physical Performance Battery is 0, and the maximum value is 12, the higher the score, the better the outcome.	An average of 1 to 2 years
The prevalence and incidence of mild cognitive impairment using a population-based survey	Mild cognitive impairment was measured using Mini-Mental State Examination collected by questionnaire.The minimum value of the Mini-Mental State Examination is 0, and the maximum value is 30, the higher the score, the better the outcome.	An average of 1 to 2 years
The prevalence and incidence of dementia using a population-based survey	Dementia was determined by diagnosis of hospitalization or diagnosis of death or Clinical Dementia Rating scale. The minimum value of the Clinical Dementia Rating is 0, and the maximum value is 3, the higher the score, the worse the outcome.	An average of 1 to 2 years
The conversion rate of normal to mild cognitive impairment	Percentage of enrolled population that convert from normal to mild cognitive impairment	An average of 1 to 2 years
The conversion rate of mild cognitive impairment to dementia	Percentage of enrolled population that convert from mild cognitive impairment to dementia	An average of 1 to 2 years
The genetic and environmental factors for mild cognitive impairment and dementia at genomic and expression levels	Discover risk factors including genetic susceptibility loci (APOE genes and other risk genes) using gene sequencing, cardiovascular risk factors (blood glucose, cholesterol, homocysteine) using laboratory tests, and unhealthy lifestyle using questionnaire.	An average of 1 to 2 years
The biomarkers for normal, mild cognitive impairment, and dementia diagnosis	Humoral biomarkers are included Aβ42, Aβ40, phosphated tau and total tau in plasma, cerebrospinal fluid, saliva, and urine. Imaging biomarkers are included cerebral volume, glucose metabolism, amyloid and tau deposition of whole brain or hippocampus.	An average of 1 to 2 years
The prevalence and incidence of movement disorder using a population-based survey	Movement disorder was measured using Short Physical Performance Battery collected by questionnaire.The minimum value of the Short Physical Performance Battery is 0, and the maximum value is 12, the higher the score, the better the outcome.	An average of 1 to 2 years

Collaborators and Investigators

• Sponsor: Xuanwu Hospital, Beijing
• Investigators: Principal Investigator: Yi Tang, MD., PhD, Xuanwu Hospital, Beijing

Study record dates

Study Major Dates

• Study Start (Actual): February 20, 2023
• Primary Completion (Estimated): May 1, 2063
• Study Completion (Estimated): May 1, 2063

Study Registration Dates

• First Submitted: April 16, 2024
• First Submitted That Met QC Criteria: April 28, 2024
• First Posted (Actual): May 1, 2024

Study Record Updates

• Last Update Posted (Actual): June 20, 2024
• Last Update Submitted That Met QC Criteria: June 17, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: Disability, Ageing, Cohort
• Other Study ID Numbers: 2022234

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No